Apremilast in Pediatric Patients With Moderate to Severe Plaque Psoriasis: 16-Week Efficacy and Safety Results From the Phase 3, Randomized, Double-Blind, Placebo-Controlled SPROUT Study

被引：0
|
作者：
Fiorillo, Loretta [1 ]
Becker, Emily [2 ]
de Lucas, Raul [3 ]
Belloni-Fortina, Anna [4 ]
Maes, Peter [5 ]
Oberoi, Rajneet K. [5 ]
Paris, Maria [5 ]
Zhang, Wendy [5 ]
Zhang, Zuoshun [5 ]
Arkin, Lisa
机构：
[1] Univ Alberta, Stollery Childrens Hosp, Edmonton, AB, Canada
[2] Driscoll Childrens Hosp, Corpus Christi, TX USA
[3] Hosp Univ La Paz PPDS, Madrid, Spain
[4] Azienda Osped Univ Padova, Padua, Italy
[5] Amgen Inc, Thousand Oaks, CA USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
42163
引用
收藏
页码：AB122 / AB122
页数：1
相关论文
共 50 条
  • [41] Infliximab monotherapy for Chinese patients with moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled multicenter trial
    Yang Hai-zhen
    Wang Ke
    Jin Hong-zhong
    Gao Tian-wen
    Xiao Sheng-xiang
    Xu Jin-hua
    Wang Bao-xi
    Zhang Fu-ren
    Li Chun-yang
    Liu Xiao-ming
    Tu Cai-xia
    Ji Su-zhen
    Shen Yang
    Zhu Xue-jun
    CHINESE MEDICAL JOURNAL, 2012, 125 (11) : 1845 - 1851
  • [42] Relationship of serum vitamin D with psoriasis severity and adalimumab response in Chinese patients with moderate to severe plaque psoriasis from a phase 3, randomized, placebo-controlled, double-blind study
    Zhang, Jianzhong
    Geng, Ziqian
    Teixeira, Henrique D.
    Okun, Martin M.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB267 - AB267
  • [43] Efficacy and Safety of Adalimumab among Patients with Moderate to Severe Psoriasis with Co-Morbidities Subanalysis of Results from a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial
    Kimball, Alexa B.
    Bensimon, Arielle G.
    Guerin, Annie
    Yu, Andrew P.
    Wu, Eric Q.
    Okun, Martin M.
    Bao, Yanjun
    Gupta, Shiraz R.
    Mulani, Parvez M.
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2011, 12 (01) : 51 - 62
  • [44] Secukinumab treatment shows a neutral effect on the lipid profile of patients with moderate to severe plaque psoriasis: Results from a randomized, double-blind, placebo-controlled, phase II study
    Mrowietz, Ulrich
    Qureshi, Abrar
    Escrig, Cesar
    Richards, Hanno
    Thurston, Helen
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 68 (04) : AB212 - AB212
  • [45] A Phase 2A, randomised, double-blind, placebo-controlled study to evaluate efficacy and safety of PF-06700841 in patients with moderate-to-severe plaque psoriasis
    Forman, S.
    Pariser, D. M.
    Poulin, Y.
    Vincent, M. S.
    Gilbert, S. A.
    Kieras, E. M.
    Qiu, R.
    Yu, D.
    Papacharalambous, J.
    Peeva, E.
    EXPERIMENTAL DERMATOLOGY, 2018, 27 : 37 - 37
  • [46] Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: Subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study
    Ohtsuki, Mamitaro
    Morita, Akimichi
    Abe, Masatoshi
    Takahashi, Hidetoshi
    Seko, Noriko
    Karpov, Alexander
    Shima, Tomohiro
    Papavassilis, Charis
    Nakagawa, Hidemi
    JOURNAL OF DERMATOLOGY, 2014, 41 (12): : 1039 - 1046
  • [47] Efficacy and safety of adalimumab in treatment of moderate to severe hidradenitis suppurativa: Results from the placebo-controlled portion of a phase II, randomized, double-blind study
    Kimball, A.
    Jemec, G.
    Okun, M.
    Gu, Y.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2011, 64 (02) : AB155 - AB155
  • [48] A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Talactoferrin in Patients With Severe Sepsis
    Guntupalli, Kalpalatha
    Dean, Nathan
    Morris, Peter E.
    Bandi, Venkata
    Margolis, Benjamin
    Rivers, Emanuel
    Levy, Mitchell
    Lodato, Robert F.
    Ismail, Preeti M.
    Reese, Amber
    Schaumberg, John P.
    Malik, Rajesh
    Dellinger, R. Phillip
    CRITICAL CARE MEDICINE, 2013, 41 (03) : 706 - 716
  • [49] Efficacy and safety of adalimumab in treatment of moderate to severe hidradenitis suppurativa: results from the placebo-controlled portion of a phase II, randomized, double-blind study
    Kimball, A. B.
    Jemec, G.
    Gu, Y.
    Okun, M.
    BRITISH JOURNAL OF DERMATOLOGY, 2011, 165 : 6 - 6
  • [50] EFFICACY AND SAFETY OF RISANKIZUMAB: RESULTS FROM TWO DOUBLE-BLIND, PLACEBO- AND USTEKINUMAB-CONTROLLED, PHASE 3 TRIALS IN MODERATE-TO-SEVERE PLAQUE PSORIASIS
    Gordon, Kenneth B.
    Strober, Bruce
    Lebwohl, Mark
    Augustin, Matthias
    Blauvelt, Andrew
    Poulin, Yves
    Papp, Kim A.
    Sofen, Howard
    Puig, Lluis
    Foley, Peter
    Ohtsuki, Mamitaro
    Flack, Mary
    Geng, Ziqian
    Gu, Yihua
    Valdes, Joaquin M.
    Thompson, Elizabeth H. Z.
    Bachelez, Herve
    ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 28 - 29
12345